- Home
- SWIN vs FGEN Comparison
SWIN vs FGEN Comparison
Compare SWIN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- FGEN
- Stock Information
- Founded
- SWIN 2017
- FGEN 1993
- Country
- SWIN Hong Kong
- FGEN United States
- Employees
- SWIN N/A
- FGEN N/A
- Industry
- SWIN
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- FGEN Health Care
- Exchange
- SWIN Nasdaq
- FGEN Nasdaq
- Market Cap
- SWIN 214.1M
- FGEN 33.5M
- IPO Year
- SWIN 2023
- FGEN 2014
- Fundamental
- Price
- SWIN $3.93
- FGEN $7.03
- Analyst Decision
- SWIN
- FGEN Strong Buy
- Analyst Count
- SWIN 0
- FGEN 1
- Target Price
- SWIN N/A
- FGEN $250.00
- AVG Volume (30 Days)
- SWIN 208.1K
- FGEN 43.0K
- Earning Date
- SWIN 08-21-2025
- FGEN 08-12-2025
- Dividend Yield
- SWIN N/A
- FGEN N/A
- EPS Growth
- SWIN N/A
- FGEN N/A
- EPS
- SWIN N/A
- FGEN N/A
- Revenue
- SWIN $3,316,000.00
- FGEN $6,996,000.00
- Revenue This Year
- SWIN $29.79
- FGEN N/A
- Revenue Next Year
- SWIN $54.60
- FGEN N/A
- P/E Ratio
- SWIN N/A
- FGEN N/A
- Revenue Growth
- SWIN N/A
- FGEN N/A
- 52 Week Low
- SWIN $1.16
- FGEN $4.50
- 52 Week High
- SWIN $4.40
- FGEN $29.00
- Technical
- Relative Strength Index (RSI)
- SWIN 62.05
- FGEN 50.17
- Support Level
- SWIN $3.70
- FGEN $7.04
- Resistance Level
- SWIN $3.99
- FGEN $7.56
- Average True Range (ATR)
- SWIN 0.35
- FGEN 0.49
- MACD
- SWIN -0.03
- FGEN -0.00
- Stochastic Oscillator
- SWIN 93.02
- FGEN 12.53
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.